Our work
Here you can find the latest news related to our company, project and collaborators.
01
The company has successfully secured €2 million in a new funding round led by Clave Capital, the company’s main investor, to accelerate its clinical development roadmap.
02
Nominated in the "CreaEmpresa" category, this prestigious recognition honors our CEO’s leadership and D-Sight’s mission to generate a positive social impact through disruptive biotechnology and innovative solutions for global eye health.
03
In its 2025 annual review of the local ecosystem, L'Econòmic has identified D-Sight as one of the ten most promising companies in Catalonia, highlighting its solid business model and its ability to attract investment in an increasingly demanding market for health technology.
04
Recognized as the most disruptive company in this year’s edition of the awards promoted by CaixaBank and ENISA,
D-Sight continues to lead the development of non-invasive therapies for diabetic retinopathy and glaucoma, reinforcing its position as a global benchmark in biotechnology.
05
Chosen from over 350 candidates in Spain’s largest positive impact competition, D-Sight will now compete to represent the Health Category in the grand final, showcasing its commitment to high-impact social innovation.
06
In this role, our CEO will serve as the key figure for Norrsken’s health subcommunity, leading its development and bridging the gap between its members and essential stakeholders across the healthcare and technology sectors.
07
​This recognition highlights D-Sight as one of the most promising startups in the Catalan ecosystem.
08
This nomination recognizes our CEO's professional career and her role as a female leader in the STEM sector, highlighting her commitment to fostering an inclusive entrepreneurial culture and serving as an inspiration for future generations of women in technology and science.
09
This award, promoted by Women Startup Community, to celebrate female-led technological success, honors D-Sight’s social impact and its innovative drug delivery system for treating diabetic retinopathy, positioning the company as a key reference in the health-tech revolution.
10
This award, presented by the association Dones en Xarxa, recognizes D-Sight's innovative potential and leadership in the health technology sector, specifically for its progress in developing a non-invasive treatment for early-stage diabetic retinopathy.
11
This recognition from the Young Entrepreneurs Association of Catalonia (AIJEC) highlights D-Sight’s commitment to innovation and its pioneering contribution to the treatment of diabetic retinopathy through its non-invasive therapeutic solution.
12
This initiative, spearheaded by ENISA and Spain Up Nation, identifies and honors the 101 most innovative startups across the country, highlighting the entrepreneurial talent driving Spain’s economic transformation and global competitiveness.
13
This is a global repository of female role models in our entrepreneurial and business ecosystem, coordinated by WITH in collaboration with ENISA.
14
This groundbreaking collaboration will streamline the production process and ensure the highest quality standards for our innovative therapeutic solution for the early treatment of diabetic retinopathy.
15
This certification recognises the character of innovative and scalable entrepreneurship of our business model, mainly focused on the further clinical development of our solution for the early treatment of diabetic retinopathy.
16
This powerful message was shared by our CEO and co-founder, Carla Maté Goldar, in her recent interview with Óscar Condés Molinero for Nobbot as the winner of the Women Start-up Awards 2023.
17
Foment del Treball and the General Consulate of the United States in Barcelona have celebrated the end of the third Catalan edition of the Academy for Women Entrepreneurs (AWE), which has accompanied, over the last few months, 30 women entrepreneurs in the development and growth of their projects.
18
This award offers a European Funds course sponsored by FINNOVA FOUNDATION and a Master's Degree in Business Management for Entrepreneurs sponsored by IEBS for our CEO & co-founder Carla Maté Goldar.
19
The Global STEM WOMEN is a project to increase equal opportunities and gender diversity in the STEM sectors (Science, Technology, Engineering & Maths). STEM WOMEN CONGRESS (SWC) is a big event who works especially to make STEM women visible and to increase the diversity in the STEM companies.
20
D-Sight is proclaimed as one of the 50 most promising early-stage startups in Europe by EU-Startups.
D-Sight participated in the EU-Startup Podcast "The Big Pitch", where the most promising start-ups in Europe were invited to pitch on air.
21
D-Sight S.L. has been recognized as one of the most innovative projects in Europe at EIT Health InnoStars Awards 2023. In a fierce competition among 10 cutting-edge health startups, D-Sight secured this award as part of this prestigious program.
22
Carla Maté Goldar has been awarded with the Women Start-up Awards 2023, Ideation Category. This award recognises women entrepreneurs who are making their mark in the world of startups in Spain.
23
Dr. Simó has also recently pronounced the lecture of admission as a new member of the Royal Academy of Medicine of Catalonia
24
Dr. Rafael Simó receives the Joaquín Barraquer Award from the Royal Academy of Medicine of Catalonia
The recognition means the admission of the current head of the Endocrinology and Nutrition Service of the Vall d'Hebron University Hospital and of the Diabetes and Metabolism research group at VHIR as a member of the RAMC.
25
The investment will allow D-Sight to move forward with the first phase of clinical validation of its drug for early-stage diabetic retinopathy and glaucoma.
26
The company linked to the Vall d'Hebron Research Institute (VHIR) "D-Sight" has received a million euro investment from the venture capital fund Clave Capital to develop therapies for the treatment of diabetic retinopathy and other neurodegenerative diseases of the retina, such as glaucoma.
_edited.jpg)
27
The Alberto Sols award recognises his contributions to diabetes research, such as the description of the mechanisms of neurodegeneration in diabetic retinopathy and new therapeutic strategies and early neuroprotective pathways.
28
​This is the first evidence in humans that eye drops can reach the retina and modulate the action of neurons, which will change the therapeutic strategy.